Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae

Meropenem/vaborbactam (Vabomere, VAY-boh-meer) will be the first antibiotic to combine a carbapenem with a beta-lactamase inhibitor.

Adding the beta-lactamase inhibitor vaborbactam helps meropenem outsmart carbapenem-resistant superbugs, which cause about 9,000 infections in the U.S. each year.

Meropenem/vaborbactam is approved to treat complicated urinary tract infections (UTIs), including pyelonephritis. Early evidence suggests it's also effective for bacteremia, pneumonia, and intra-abdominal infections.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals